

Document and Entity Information - shares	6 Months Ended	
	Mar. 31, 2016	Nov. 07, 2016
Document and Entity Information [Abstract]		
Entity Registrant Name	MEDICAL INTERNATIONAL TECHNOLOGY INC	
Entity Central Index Key	000112372	
Amendment Flag	false	
Current Fiscal Year End Date	-09-30	
Document Type	10-Q	
Document Period End Date	Mar. 31, 2016	
Document Fiscal Year Focus	2016	
Document Fiscal Period Focus	Q2	
Entity Filer Category	Smaller Reporting Company	
Entity Common Stock, Shares Outstanding		84,304,627

Consolidated Balance Sheet (Unaudited) - USD (\$)	Mar. 31, 2016	Sep. 30, 2015
Current Assets		
Cash and cash equivalents	\$ 555,478	
Accounts receivable, net of allowance for bad debts of \$7,900 at March 31, 2016	34,736	\$ 57,031
Inventories	239,010	210,579
Prepaid expenses	11,602	7,183
Total Current Assets	840,826	274,793
Property and Equipment		
Tooling and machinery	576,965	558,706
Furniture and office equipment	132,351	128,163
Leasehold improvements	23,618	22,871
Total property and equipment	732,934	709,740
Less accumulated depreciation	(632,322)	(578,738)
Total property and equipment, net	100,612	131,002
Other Assets		
Patents (net of accumulated amortization of \$71,702 and \$56,993)	61,597	53,041
Total assets	\$ 1,003,035	458,836
Current Liabilities		
Bank line		\$ 74,663
Deferred income	\$ 12,877	
Accounts payable and accrued expenses	55,665	\$ 109,712
Advance from related party	500,000	\$ 30,000
Short term borrowings	300,000	
Current portion of long term debts	17,848	\$ 35,795
Total Current Liabilities	886,390	250,170
Total Liabilities	\$ 886,390	\$ 250,170
Commitments		
Stockholders' Equity		
Preferred stock, \$0.001 par value; 3,000,000 shares authorized; No issued and outstanding shares as of March 31, 2016 and September 30, 2015.		
Common stock, \$0.001 par value; 100,000,000 shares authorized; 84,304,627 issued and outstanding shares as of March 31, 2016 and September 30, 2015.	\$ 8,430	\$ 8,430
Additional paid-in capital	12,917,025	12,917,025
Accumulated deficit	(12,457,196)	(12,330,450)
Other comprehensive loss	(351,614)	(386,339)
Total Stockholders' Equity	116,645	208,666
Total Liabilities and Stockholders' Equity	\$ 1,003,035	\$ 458,836

Consolidated Balance Sheet (Parenthetical) (Unaudited) - USD (\$)	Mar. 31, 2016	Sep. 30, 2015
Balance Sheet [Abstract]		
Accounts receivable, allowance for bad debt	\$ 7,900	
Net of accumulated amortization	\$ 71,702	\$ 56,993
Preferred stock, par value	\$ 0.0001	\$ 0.0001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued		
Preferred stock, shares outstanding		
Common stock, par value	\$ 0.0001	\$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	84,304,627	84,304,627
Common stock, shares outstanding	84,304,627	84,304,627

Consolidated Statements of Operations (Unaudited) - USD (\$)	3 Months Ended		6 Months Ended	
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Statements of Operations [Abstract]				
Sales	\$ 90,013	\$ 165,306	\$ 241,250	\$ 298,304
Cost of sales	(33,584)	(38,105)	(75,280)	(80,979)
Gross profit	56,429	127,201	165,970	217,325
Selling, general, and administrative expenses	(121,852)	(69,728)	(290,688)	(168,699)
Total operating expenses	(121,852)	(69,728)	(290,688)	(168,699)
Profit (loss) from operations	(65,423)	57,473	(124,718)	48,626
Other Income (Expense)				
Interest income	228	204	392	499
Interest expense	(924)	(2,931)	(2,420)	(5,329)
Other income (expense), net	(696)	(2,727)	(2,028)	(4,830)
Net profit (loss)	\$ (66,119)	\$ 54,746	\$ (126,746)	\$ 43,796
Basic profit (loss) per share	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00
Basic weighted average shares outstanding	84,304,627	84,304,627	84,304,627	84,304,627

Consolidated Statements of Cash Flows (Unaudited) - USD (\$)	6 Months Ended	
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:		
Net income (loss)	\$ (126,746)	\$ 43,796
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization expense	54,076	41,221
Changes in:		
Accounts receivable	22,295	(7,379)
Inventories	(28,431)	39,913
Prepaid expenses	(4,419)	(8,532)
Accounts payable and accrued liabilities	(54,047)	(87,484)
Deferred income	12,877	3,361
Net cash provided by (used by) operating activities	(124,395)	24,896
Cash flows from investing activities:		
Acquisition of patents	\$ (21,086)	(17,889)
Tooling and machinery		(11,212)
Net cash used by investing activities	\$ (21,086)	(29,101)
Cash flows from financing activities:		
Bank line	(74,663)	(411)
Bank loans	\$ (17,947)	(29,665)

Proceeds from issuance of stock, net		50,000
Increase (decrease) in amounts due to related parties	\$ 470,000	\$ (20,000)
Proceeds from short term borrowings	\$ 300,000	
Repayment on notes payable		\$ (30,000)
Net cash used by financing activities	\$ 677,390	(30,076)
Effect of exchange rates	23,569	45,424
Increase in cash	\$ 555,478	11,143
Cash, beginning of period		33,767
Cash, end of period	\$ 555,478	44,910
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 2,028	\$ 5,329
Cash paid for federal income taxes		

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD (\$)	6 Months Ended	
	Mar. 31, 2016	Mar. 31, 2015
Statements of Comprehensive Loss [Abstract]		
Net income (loss)	\$ (126,746)	\$ 43,796
Other comprehensive income (loss)		
Foreign currency translation adjustment	34,725	7,671
Net comprehensive income (loss)	\$ (92,021)	\$ 51,467

Basis of Presentation	6 Months Ended	
	Mar. 31, 2016	
Basis of Presentation [Abstract]		
Basis of Presentation	Note 1 – Basis of Presentation	
	Interim Financial Statements	
	<p>The accompanying unaudited condensed consolidated financial statements of Medical International Technology, Inc. ("MIT" or the "Company") and its subsidiary (collectively referred to as the "Company") have been prepared in accordance with accounting principles generally accepted in the United States of America, pursuant to the rules and regulations of the Securities and Exchange Commission. All significant intercompany balances and transactions have been eliminated. These financial statements do not include all information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. It is recommended that these interim unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2015.</p> <p>In the opinion of management, all adjustments (consisting only of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six month periods ended March 31, 2016 are not necessarily indicative of the results which may be expected for any other interim periods or for the year ending September 30, 2016. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> <p>Going concern</p> <p>There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.</p> <p>The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.</p>	

Inventories	6 Months Ended	
	Mar. 31, 2016	
Inventories [Abstract]		
Inventories	Note 2 – Inventories	
	Inventories at March 31, 2016 and September 30, 2015 consist of the following:	
	<p>Raw materials</p> <p>Work in process</p> <p>Finished goods</p> <p>Total</p>	

Property and Equipment	6 Months Ended	
	Mar. 31, 2016	
Property and Equipment [Abstract]		
Property and Equipment	Note 3 – Property and Equipment	
	<p>The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years. Depreciation is computed on the straight-line method for financial reporting purposes and on the declining balance method for income tax reporting purposes. Depreciation expense for the six months ended March 31, 2016 and 2015 was \$40,746 and \$31,260, respectively</p>	

Intangible Assets	6 Months Ended	
	Mar. 31, 2016	
Intangible Assets [Abstract]		
Intangible Assets	Note 4 – Intangible Assets	
	<p>As of March 31, 2016 the Company has net patents on certain technologies aggregating \$61,597. Amortization expense for the six months ended March 31, 2016 and 2015 were \$13,330 and \$9,961, respectively. costs on its needle-free injector of \$21,086. Following is a detail of patents at March 31, 2016.</p>	
	Gross Intangible Assets	Accumulated Amortization
Patents	\$ 133,299	\$

Joint venture agreement	6 Months Ended	
	Mar. 31, 2016	
Joint venture agreement [Abstract]		
Joint venture agreement	Note 5 – Joint venture agreement	
	<p>On May 6, 2009, the Company entered into a certain joint venture agreement (the "Joint Venture Agreement") with Jiangsu Hualan Biotechnology Ltd. (China) ("Jiangsu Hualan"). Pursuant to the Joint Venture Agreement, the parties thereto established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT China) Ltd. ("MIT China" or the "Joint Venture"), focusing on research, production and sales of medical equipments, import and export of medical equipments and components products, especially Needle-Free Jet Injector products. The total investment by the Joint Venture shall amount to \$2,000,000, and the registered capital shall amount to \$1,400,000. The Company invested cash of \$426,678 and transferred the license rights to produce and sell the Company's needle-free injectors products into the Joint Venture. The license rights were valued at \$280,000 under the agreement. The contributions by the Company resulted in the Company owning 49% of the registered capital of the Joint Venture. Jiangsu Hualan contributed cash of \$714,000, and owns 51% of the registered capital.</p> <p>Under the Joint Venture Agreement, the Company appointed 1 member, and Jiangsu Hualan appointed 2 members, to the board of directors of the Joint Venture. Profits of the Joint Venture will be allocated based upon each party's investment in the registered capital.</p> <p>In March 2012, MIT China agreed and sold 9% of the joint venture for an investment of 18,000,000 RMB (US\$3,000,000). Jiangsu Hualan now has 46.41%, the Company has 44.59%, and Taizhou Amazon Investment Center has 9% ownership in the MIT China joint venture.</p> <p>The Company accounts for its investment in MIT China in accordance with Financial Accounting Standards Board Accounting Standards Codification 323, "Investment — Equity Method and Joint Venture" (ASC 323), previously referred to as Accounting Principles Board Opinion No. 18, "The Equity Method of Accounting for Investments in Common Stock." Accordingly, the Company adjusts the carrying amount of its investment in MIT China to recognize its share of earnings or losses. As of March 31, 2016 and September 30, 2015, the Company's had no recorded investment remaining in the MIT China.</p> <p>During the six and three months ended March 31, 2016, the Company had \$95,610 and \$51,780 in sales of products to the joint venture. As of March 31, 2016 and September 30, 2015, the Company had a receivable from the joint venture of \$32,390 and \$51,165, respectively.</p>	

During the six and three months ended March 31, 2015, the Company had approximately \$127,000 and \$61,000 in sales of products to the joint venture.

As of March 31, 2016 and September 30, 2015, the Company had an advance from the joint venture of \$500,000 and \$0, respectively. The advance bears no interest and has no formal payment terms.

Bank Line	6 Months Ended Mar. 31, 2016
Bank Line [Abstract]	
Bank Line	<p>Note 6 – Bank Line</p> <p>The Company, through a hypothec agreement, has a line of credit up to a maximum of \$100,000. The line is secured by Investissement Quebec (a Quebec government entity) and by Karim Menassa (personally) and by account receivables, inventories, equipment and all other assets of the Company. The line bears interest at the prime rate plus 2.5% (5.75% at September 30, 2015). At March 31, 2016 and September 30, 2015, the Company had \$0 and \$74,663 outstanding under the agreement.</p>

Related Party Transactions	6 Months Ended Mar. 31, 2016
Related Party Transactions [Abstract]	
Related Party Transactions	<p>Note 7 – Related Party Transactions</p> <p>Related party balances consist of the following at March 31, 2016 and September 30, 2015:</p> <p>Payable to 9211-0766 Quebec Inc – interest at 8%, due December 31, 2015 Advance from MIT China – no interest, no maturity date</p> <p>During the six and three months ended March 31, 2016, the Company paid approximately \$107,000 and \$25,000 to a company owned by the President and CEO for consulting fees. During the six and three months ended March 31, 2015, the Company paid approximately \$56,300 and \$8,300 to a company owned by the President and CEO for consulting fees.</p>

Stockholders' Equity (Deficit)	6 Months Ended Mar. 31, 2016
Stockholders' Equity (Deficit) [Abstract]	
Stockholders' Equity (Deficit)	<p>Note 8 – Stockholders' Equity (Deficit)</p> <p>Issuance of Common Stock</p> <p>From time to time, the Company will issue common stock for services rendered, debt reductions or as part of private placement offerings. For the three and six months ended March 31, 2016, there was no common stock issuance.</p> <p>Preferred Stock</p> <p>As of March 31, 2016, there was no preferred stock outstanding. Dividend features and voting rights are at the discretion of the Board of Directors without the requirement of shareholder approval.</p> <p>Outstanding Options</p> <p>As of March 31, 2016 and 2015, there are no options outstanding to purchase shares of the Company's common stock.</p> <p>Outstanding Warrants</p> <p>There are no outstanding warrants</p>

Operating Leases	6 Months Ended Mar. 31, 2016
Operating Leases [Abstract]	
Operating Leases	<p>Note 9 – Operating Leases</p> <p>The Company leases its office and warehouse space under an operating lease that expires on December 31, 2021. The lease calls for a monthly rent of \$3,600 (CND). Rent expense for the three months ended March 31, 2016 and September 30, 2015 was \$10,800 and \$9,000, respectively.</p> <p>Future minimum lease commitments pertaining to the lease expire as follow:</p> <p>Year ended</p> <p>March 31, 2017 March 31, 2018 March 31, 2019 March 31, 2020 March 31, 2021</p>

Debt	6 Months Ended Mar. 31, 2016
Debt [Abstract]	
Debt	<p>Note 10 – Debt</p> <p>Debt consists of the following at March 31, 2016 and September 30, 2015:</p> <p>Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016. Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of \$5,035 (CND) through May 2016. Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity date</p> <p>Total debt (all current)</p>

Contingencies	6 Months Ended Mar. 31, 2016
Contingencies [Abstract]	
Contingencies	<p>Note 11 – Contingencies</p> <p>Legal Proceedings</p> <p>We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.</p>

Inventories (Tables)	6 Months Ended Mar. 31, 2016
Inventories [Abstract]	
Schedule of inventories	<p>Raw materials Work in process Finished goods Total</p>

Intangible Assets (Tables)		6 Months Ended	
		Mar. 31, 2016	
Intangible Assets [Abstract]			
Summary of patents			
		Gross Intangible Assets	Accumulated Amortization
Patents		\$ 133,299	\$

Related Party Transactions (Tables)		6 Months Ended	
		Mar. 31, 2016	
Related Party Transactions [Abstract]			
Schedule of related party transactions			
	Payable to 9211-0766 Quebec Inc – interest at 8%, due December 31, 2015		
	Advance from MIT China – no interest, no maturity date		

Operating Leases (Tables)		6 Months Ended	
		Mar. 31, 2016	
Operating Leases [Abstract]			
Schedule of future minimum lease commitments			
	Year ended		
	March 31, 2017		
	March 31, 2018		
	March 31, 2019		
	March 31, 2020		
	March 31, 2021		

Debt (Tables)		6 Months Ended	
		Mar. 31, 2016	
Debt [Abstract]			
Schedule of long-term debt			
	Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016.		
	Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of \$5,035 (CND) through May 2016.		
	Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity date		
	Total debt (all current)		

Inventories (Details) - USD (\$)	Mar. 31, 2016	Sep. 30, 2015
Components of inventories		
Raw materials	\$ 153,108	\$ 136,842
Work in process	52,635	51,511
Finished goods	33,267	22,226
Total	\$ 239,010	\$ 210,579

Property and Equipment (Details) - USD (\$)		6 Months Ended	
		Mar. 31, 2016	Mar. 31, 2015
Property And Equipment (Textual)			
Property and equipment estimated useful lives			
The cost of property and equipment is depreciated over the estimated useful lives of the related assets, which range from 5 to 7 years.			
Depreciation expense		\$ 40,746	\$ 31,260

Intangible Assets (Details) - USD (\$)	6 Months Ended	
	Mar. 31, 2016	Sep. 30, 2015
Detail of patents		
Accumulated amortization	\$ 71,702	\$ 56,993
Net Intangible Assets	61,597	\$ 53,041
Patents [Member]		
Detail of patents		
Gross Intangible Assets	133,299	
Accumulated amortization	71,702	
Net Intangible Assets	\$ 61,597	
Patents [Member] Maximum [Member]		
Detail of patents		
Weighted Average Life (Years)	15 years	
Patents [Member] Minimum [Member]		
Detail of patents		
Weighted Average Life (Years)	7 years 6 months	

Intangible Assets (Details Textual) - USD (\$)	6 Months Ended		
	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015
Intangible Assets (Textual)			
Aggregate net patents	\$ 61,597		\$ 53,041
Amortization expenses	13,330	\$ 9,961	
Capitalized patent costs on needle-free injector	\$ 21,086		

Joint venture agreement (Details)	May. 06, 2009 USD (\$) Members	1 Months Ended		3 Months Ended		6 Months Ended		Sep. 30, 2015 USD (\$)	Mar. 31, 2012 CNY (¥)
		Mar. 31, 2012 USD (\$)	Mar. 31, 2016 USD (\$)	Mar. 31, 2015 USD (\$)	Mar. 31, 2016 USD (\$)	Mar. 31, 2015 USD (\$)	Mar. 31, 2016 USD (\$)		
Joint Venture Agreement (Textual)									
Ownership percentage	49.00%	44.59%							44.59%
Cash invested in joint venture		\$ 3,000,000							¥ 18,000,000
Number of members appointed under joint venture agreement Members	1								
Total investment to be made by joint venture	\$ 2,000,000								
Registered capital	1,400,000								
Investment in joint venture	426,678								
Value of license rights	\$ 280,000								
Sale of joint venture percentage for an investment by parent company		9.00%							
Sale of products to joint venture, amount			\$ 51,780	\$ 61,000	\$ 95,610	\$ 127,000			
Receivable from the joint venture			32,390		32,390		\$ 51,165		
Advance from the joint venture			\$ 500,000		\$ 500,000		\$ 0		
Jiangsu Hualan [Member]									
Joint Venture Agreement (Textual)									
Ownership percentage	51.00%	46.41%							46.41%
Cash invested in joint venture	\$ 714,000								
Number of members appointed under joint venture agreement Members	2								
Taizhou Amazon Investment Center [Member]									
Joint Venture Agreement (Textual)									

Bank Line (Details) - USD (\$)	6 Months Ended	
	Mar. 31, 2016	Sep. 30, 2015
Bank Line (Textual)		
Maximum equipment line of credit	\$ 100,000	
Amount outstanding	\$ 0	\$ 74,663
Interest prime rate	2.50%	
Line bears interest rate		5.75%

Related Party Transactions (Details) - USD (\$)	6 Months Ended	
	Mar. 31, 2016	Sep. 30, 2015
Related Party Transactions [Abstract]		
Payable to 9211-0766 Quebec Inc. - interest at 8%, due December 31, 2015		\$ 30,000
Advance from MIT China - no interest, no maturity date	\$ 500,000	0
Advance from related party	\$ 500,000	\$ 30,000

Related Party Transactions (Details Textual) - USD (\$)	3 Months Ended		6 Months Ended	
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Related Party Transaction (Textual)				
Interest rate percent	8.00%		8.00%	
CEO [Member]				
Related Party Transaction (Textual)				
Consulting fees	\$ 25,000	\$ 8,300	\$ 107,000	\$ 56,300
President [Member]				
Related Party Transaction (Textual)				
Consulting fees	\$ 25,000	\$ 8,300	\$ 107,000	\$ 56,300

Operating Leases (Details)	Mar. 31, 2016 USD (\$)
Operating Leases [Abstract]	
March 31, 2017	\$ 27,000
March 31, 2018	30,000
March 31, 2019	30,000
March 31, 2020	30,000
March 31, 2021	30,000
Operating leases, future minimum payments, Total	\$ 147,000

Operating Leases (Details Textual)	6 Months Ended	
	Mar. 31, 2016 USD (\$)	Mar. 31, 2016 CAD
Operating Leases (Textual)		
Expiry date of operating lease	Dec. 31, 2021	Dec. 31, 2021
Monthly rent for office and warehouse space		CAD 3,600
Rent expense \$	\$ 20,500	

Debt (Details) - USD (\$)	Mar. 31, 2016	Sep. 30, 2015
Schedule of long-term debt		
Note payable to a bank, bearing interest at prime plus 3% (6.25% at September 30, 2015), secured by equipment, due December 20, 2016.	\$ 13,964	\$ 24,515
Loan Canada Economic Development, no interest, repayment of the contribution in sixteen (16) Equal and consecutive quarterly installments of \$5,035 (CAD) through May 2016.	3,884	\$ 11,280
Short term borrowing payable to an individual, bearing zero interest and no payment terms or maturity date	300,000	
Total debt (all current)	\$ 17,848	\$ 35,795

Debt (Details Textual)	6 Months Ended		12 Months Ended
	Mar. 31, 2016 CAD	Members	Sep. 30, 2015
Note Payable to Bank [Member]			
Debt (Textual)			
Interest rate in addition to prime rate		3.00%	6.25%
Debt maturity date	Dec. 20, 2016		
Canada Economic Development [Member]			
Debt (Textual)			
Number of consecutive installments for repayment of long-term debt Members		16	
Amount of each installment		CAD 5,035	
Debt maturity date	May 31, 2016		
Due date description of first installment	Sixteen (16) Equal and consecutive quarterly installments		

The rendering log information

Info : In "Consolidated Balance Sheet (Unaudited)", column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.
 Info : In "Consolidated Statements of Cash Flows (Unaudited)", column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.
 Info : In "Consolidated Statements of Comprehensive Income (Loss) (Unaudited)", column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.